SM
FATE icon

SG3 Management’s Fate Therapeutics FATE Stock Holding History

SG3 Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,000
Closed -$1.16M – 540
2022
Q1 		$1.16M Buy
+30,000
New +$1.16M 0.03% 425
2021
Q2 		– Sell
-24,000
Closed -$1.98M – 1116
2021
Q1 		$1.98M Buy
24,000
+21,700
+943% +$2.08M 0.05% 410
2020
Q4 		$209K Buy
+2,300
New +$143K ﹤0.01% 861

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

SG3 Management's FATE Position: Q2 2022 in Review

SG3 Management sold out of Fate Therapeutics (FATE) in Q2 2022, closing a stake of 30,000 shares — an estimated $1.16M sold.

SG3 Management first reported a position in FATE in Q4 2020 and held it in 3 quarters. The position peaked at $1.98M in Q1 2021. 233 funds tracked by Wall St. Rank hold FATE as of Q2 2022.

  • SG3 Management reported no remaining Fate Therapeutics position as of Q2 2022 after selling out during the quarter.
  • SG3 Management sold 30,000 Fate Therapeutics shares in Q2 2022, an estimated $1.16M.
  • SG3 Management first reported a position in Fate Therapeutics in Q4 2020 and held it in 3 quarters.
  • SG3 Management's Fate Therapeutics position peaked at $1.98M in Q1 2021.
  • 233 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2022.

Based on SG3 Management's 13F filing for Q2 2022, filed 15 Aug 2022.